登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，9月25日，Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-10-14

  • Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay

    Jianhui Nie, Qianqian Li, Jiajing Wu, Chenyan Zhao, Huan Hao, Huan Liu, Li Zhang, Lingling Nie, Haiyang Qin, Meng Wang, Qiong Lu, Xiaoyu Li, Qiyu Sun, Junkai Liu, Changfa Fan, Weijin Huang, Miao Xu & Youchun Wang

    Nature Protocols (2020)

    Abstract

    Pseudotyped viruses are useful virological tools because of their safety and versatility. On the basis of a vesicular stomatitis virus (VSV) pseudotyped virus production system, we developed a pseudotyped virus-based neutralization assay against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in biosafety level 2 facilities. Compared with the binding antibody test, the neutralization assay could discriminate the protective agents from the antibody family. This protocol includes production and titration of the SARS-CoV-2 S pseudotyped virus and the neutralization assay based on it. Various types of samples targeting virus attachment and entry could be evaluated for their potency, including serum samples derived from animals and humans, monoclonal antibodies and fusion inhibitors (peptides or small molecules). If the pseudotyped virus stock has been prepared in advance, it will take 2 days to get the potency data for the candidate samples. Experience in handling cells is needed before implementing this protocol.

  • 原文来源：https://www.nature.com/articles/s41596-020-0394-5
85浏览量
原文链接
相关报告

  • 《Nature，3月25日，Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2021-03-29
    • Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice Raoul De Gasparo, Mattia Pedotti, […]Luca Varani Nature (2021) Abstract Neutralizing antibodies targeting the receptor binding domain (RBD) of the SARS-CoV-2 Spike (S) are among the most promising approaches against coronavirus disease 2019 (COVID-19)1,2. We developed a bispecific, IgG1-like molecule (CoV-X2) based on two antibodies derived from COVID-19 convalescent donors, C121 and C1353. CoV-X2 simultaneously binds two independent sites on the RBD and, unlike its parental antibodies, prevents detectable S binding to Angiotensin-Converting Enzyme 2 (ACE2), the virus cellular receptor. Furthermore, CoV-X2 neutralizes SARS-CoV-2 and its variants of concern, as well as the escape mutants generated by the parental monoclonals. In a novel animal model of SARS-CoV-2 infection with lung inflammation, CoV-X2 protects mice from disease and suppresses viral escape. Thus, simultaneous targeting of non-overlapping RBD epitopes by IgG-like bispecific antibodies is feasible and effective, combining into a single molecule the advantages of antibody cocktails.
    174浏览量
    原文链接

  • 《Nature，10月29日，Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-11-18
    • Quantification of antibody avidities and accurate detection of SARS-CoV-2 antibodies in serum and saliva on plasmonic substrates Tiancheng Liu, Jessica Hsiung, Su Zhao, Jessica Kost, Deepika Sreedhar, Carl V. Hanson, Kjerstie Olson, Douglas Keare, Shin Ting Chang, Kevin P. Bliden, Paul A. Gurbel, Udaya S. Tantry, John Roche, Cynthia Press, John Boggs, Jorge P. Rodriguez-Soto, Jose G. Montoya, Meijie Tang & Hongjie Dai Nature Biomedical Engineering (2020) Abstract Accurate assays for the detection of antibodies to SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) are essential for the control of the COVID-19 (coronavirus disease 2019) pandemic. Here, we report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva, and for quantifying immunoglobulin avidities against coronavirus antigens from SARS-CoV-2, SARS-CoV-1 and the common-cold viruses OC43, HKU1, NL63 and 229E. The antibody assay detected immunoglobulin M in 87% (52 of 60) COVID-19-positive serum samples collected 6 or more days after symptom onset (and the immunoglobulins M and G in all 33 samples collected at least 15 days after symptom onset), and correctly classified 456 out of the 457 COVID-19-negative serum samples tested (424 of them collected before the pandemic, including 73 that were positive for other viruses). We used the antibody-avidity assay to study antibody-maturation patterns, anamnestic responses, and cross-immunity to the common-cold coronaviruses.
    26浏览量
    原文链接